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Drug-eluting microspheresPurpose: The purpose of this study was to evaluate the efficiency of transarterial
chemoembolization using drug eluting microspheres loaded with irinotecan in the treat-
ment of the colorectal liver metastases after failure of chemotherapy.
Patients and methods: This prospective study was conducted from March 2014 to June
2016. The patients including 16 men and 6 women (mean age, 55 years) with metastatic
colorectal carcinoma to the liver underwent transarterial chemoembolization using drug
eluting microspheres as a salvage therapy after failure of systemic chemotherapy. Each
patient underwent 18F-FDG PET/CT study before the procedure as well as 2 and 4 months
after it to assess the response to therapy.
Results: Favorable response was seen in 13 patients (59.1% of patients), progression of the
disease occurred in 3 patients (13.6% of patients) while stationary disease was seen in 5
patients (22.7% of patients) and one patient died from brain metastases before the 2
months follow-up.
Conclusion: Transarterial chemoembolization using drug-eluting microspheres loaded
with irinotecan is a safe and effective salvage treatment of liver metastases from colorectal
carcinoma not responding to systemic chemotherapy.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by
Elsevier. This is an open access article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/4.0/).1. Introduction
Advanced colorectal carcinoma with development of
hepatic metastases leads to poor prognosis unless lesion
resection is possible. Unfortunately, about 80% of patients
with hepatic metastases are unsuitable candidates for rad-
ical resection and liver metastatic disease is considered as
life limiting for the majority of patients. Systemicchemotherapy can cause regression of activity, size and
number of hepatic metastases; yet, local therapy could be
used in non responding cases and may be helpful for
long-term survival. Transarterial chemoembolization
(TACE) was introduced several years ago (as a local ther-
apy) in order to provide high concentration of the
chemotherapeutic agent within the lesion. This technique
leads to stable disease or partial response in 60–75% of
patients with liver metastases [1–3].
Chemoembolization using drug eluting microspheres
(DEM TACE) was developed to prolong the release of
chemotherapeutic agent within the tumor in a prolonged
and slow manner. Microspheres (HepaSphereTM Micro-
spheres) 30–60 lm are able to absorb chemotherapeutic
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microspheres get larger size to 100–200 lm and slowly
release the cytotoxic drug. The advantage of DEM TACE is
to increase the concentration of chemotherapeutic agent
within the tumor, with decreased systemic side effects
and toxicity [4,5]. Additionally, the arterial supply of the
tumor is embolized by the spheres inducing ischemic
effect [6,7].
PET/CT using 18F-FDG can reveal the metabolic infor-
mation of tumor tissues at the molecular level and can
be used to diagnose malignancy with high sensitivity and
specificity. Because changes in tissue metabolism always
precede changes in tissue structure, PET/CT can be used
to assess the early response after TACE treatment and to
show residual, recurring and metastasized lesions by quan-
titatively analyzing the changes in the standardized uptake
value (SUV) of the lesions before and after TACE treatment
[8–13].
The aim of this study was to evaluate safety and efficacy
of DEM TACE loaded with irinotecan in treatment of
patients with unresectable colorectal liver metastases after
failure of systemic chemotherapy, using 18F-FDG PET/CT
study as a method to assess the therapeutic response.2. Patients and methods
2.1. Patients
From March 2014 to June 2016, a total of 22 patients
(16 males and 6 females) ranging in age from 43 to
65 years (mean age, 55 years) with colorectal hepatic
metastases, after unfavorable response to systemic
chemotherapy were subjected to transcatheter arterial
chemoembolization (TACE) using drug-eluting micro-
spheres with irinotecan. The number and size of lesions
are shown in Table 1. The exclusion criteria were as fol-
lows: Child-Pugh class B and C patients, poor bleeding pro-Table 1
The number and size of the hepatic lesions in the study population.
Patient number Age Sex Other metastases
1 55 Male Yes
2 47 Male No
3 62 Male No
4 52 Female No
5 60 Male No
6 57 Male Yes
7 53 Female Yes
8 43 Male No
9 60 Male No
10 64 Male No
11 47 Female Yes
12 50 Female No
13 65 Male No
14 60 Male Yes
15 57 Male No
16 52 Male No
17 58 Female No
18 60 Female Yes
19 49 Male No
20 53 Male No
21 48 Male Yes
22 59 Male Nofile, main portal vein thrombosis and renal impairment.
Each patient underwent 18F-FDG PET/CT study before the
procedure as well as 2 and 4 months after it, to assess
the response to therapy.2.2. DEM TACE technique
Under strict sterile conditions, right femoral artery
approach was used as an access for catheterization of the
hepatic and superior mesenteric arteries as well as left gas-
tric arteries to identify the tumor arterial blood supply. A 5
or 4-French polyethylene catheter with a cobra head con-
figuration was used. The DEM TACE procedure was per-
formed using one vial of Hepasphere of size 30–60 lm
(HepaSphere, Merit medical, Utah, USA) loading 100 mg
of irinotecan. The prepared syringes were left for about
one hour to allow the microspheres to absorb the irinote-
can. Before embolization excessive fluid was removed from
syringes, the mixture was added to 10 cc of non ionic con-
trast media (Omnipaque 350).
A lobar approach was used in most of the cases and in 9
cases a microcatheter (Renegade Hi Flow, Boston Scientific,
USA) for superselective catheterization of the feeding
branches. Fourteen patients were subjected to one session
of chemoembolization and 8 patients with bilobar hepatic
metastasis had another session of intervention one month
later. After the procedure, analgesics, antibiotics and antie-
metic drugs were given.2.3. PET/CT technique
All patients were examined using a hybrid PET/CT sys-
tem (PHILIPS; Ingenuity TF 128 PET/CT scanner, USA), in
supine position from base of skull to mid thigh. The tracer
used was 18F-FDG which was injected intravenously with
a dose of 0.1 mCi/kg adjusted according to patient’s weight.Number of tumor nodules Size of the largest lesion (mm)
2 45
4 22
1 30
Multiple (>5) 34
5 30
3 65
Multiple (>5) 36
1 55
1 25
1 40
4 53
3 45
2 25
Multiple (>5) 50
5 33
4 45
3 20
Multiple (>5) 55
Multiple (>5) 35
2 40
4 50
Multiple (>5) 34
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study and their blood glucose value was kept less than
160 mg/dl at the time of the tracer injection. The time of
uptake from 18F-FDG injection to onset of emission scan
was about 60 min.
A PET emission scan was performed over several bed
positions (5–7), each with an axial field of view of approxi-
mately 15 cm per bed position with an in-plane spatial res-
olution of 4 mm. The acquisition time of emission data was
2 minperbedposition in timerangebetween13and17 min.
A 128 integrated multi-slice CT machine was used to do
the diagnostic contrast-enhanced CT images immediately
after PET scanning, covering the identical transverse field
of view. Iodinated non ionic contrast agent (Omnipaque
350) was administrated IV (100 ml) using an injector, with
an injection flow of 5 ml/s just before the beginning of the
scan. The parameters of the diagnostic CT scan were as fol-
lows: 120 mA, 130 kV, 0.5 s tube rotation time, slice thick-
ness 5 mm, 8-mm table feed and 3 mm incremental
reconstruction. All PET, CT and PET/CT images were recon-
structed andviewedonPhilipsworkstation,whichprovided
multi-planar reformatted PET, CT and fused PET/CT images
with linked cursors as well as 3D maximum intensity pro-
jection (MIP) images and PET images in video mode.Fig. 1. (a) Axial fused PET/CT image of a 60 years old female patient with multip
digital subtraction angiogram shows faint tumoral blushes (arrows); The patien
100 mg of irinotecan. (c) Follow-up axial fused PET/CT image after 4 months
metastatic deposits.2.4. Image analysis
A combined team, including onenuclearmedicinephysi-
cian and one radiologist, interpreted the PET, CT and fused
PET/CT images. They were aware of each patient’s history
and clinical data. They recorded the number, size and activ-
ity of the hepatic metastatic lesions before and after DEM
TACE. The activity of the lesions was detected qualitatively
as well as quantitatively using the Standardized Uptake
Value to assess the response to therapy.3. Results
DEMTACEof the hepatic colorectalmetastaseswas tech-
nically successful in all cases with clinical success in about
81.8% of patients. One patient died from brain metastasis 6
weeks after the procedure. Favorable response (decrease
in activity, size or number of the hepatic metastases) was
present in 13 (59.1%) patients (Figs. 1–3), while stationary
disease was seen in 5 (22.7%) patients. However, progres-
sion of the disease occurred in 3 (13.6%) patients.
There were no severe complications after the proce-
dure. The main adverse effects were right hypochondrialle right hepatic lobe metastases from colonic carcinoma. (b) Right hepatic
t underwent DEM TACE using Hepasphere of size 30–60 lm loaded with
showing favorable response with reduction of size and activity of the
Fig. 2. (a) Axial fused PET/CT image for a 43 years old male patient with a large left lobe hepatic metastatic deposit from rectal carcinoma. (b) and (c)
Hepatic angiograms show early and late tumoral stain (arrowed), the patient underwent DEM TACE using Hepasphere loaded with irinotecan. (d) Follow-up
axial fused PET/CT image after 4 months showing regression of the disease with decreased size and activity of the lesion.
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minimal ascites (13%) and anorexia (60%). The developed
post procedural ascites was mild and cytological examina-
tion of the ascitic fluid revealed absence of malignant cells.
The mean time of the procedure was 70 min and all
patients were hospitalized for a day after the procedure.
Unfortunately one patient died before the first follow-
up (not included in the post procedural response), and
two patients died before the second follow-up (70 and
133 days after TACE).4. Discussion
Although the colorectal liver metastases appear hypo-
vascular in the post contrast cross sectional examinations,
that does not indicate that they are not vascularized. A rel-
atively old post-mortem study suggests that liver metas-
tases obtain the majority of their nutrition from the
hepatic artery [14]. On the basis of the results of various
multicenter trials, it is well known that the regional
chemotherapy of liver metastases of colon cancer is much
Fig. 3. (a) PET and (b) Fused PET/CT images of a 58 years old female patient with multiple right hepatic lobe and single left lobe active metastases from
colonic carcinoma (arrows). (c) Right hepatic digital subtraction angiogram with no definite tumoral blush; DEM TACE for the right lobe was done using
Hepasphere loaded with 100 mg of irinotecan. (d) Follow-up fused PET/CT image after 2 months showing complete resolution of right lobe lesions. The left
lobe lesion is still noted (arrowed) and the patient later on underwent radiofrequency ablation for that lesion.
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an alternative strategy to control tumor progression [15].
However, the proper method of chemotherapeutic drug
delivery is still under investigation [1].
Drug eluting microspheres are widely used for hepato-
cellular carcinoma which usually has high vascularity from
the hepatic arterial branches with significant enhancement
in the arterial phase in the triphasic CT examination with
satisfactory results [16].
Jarza˛bek et al., conducted a study on 15 patients with
liver metastases from different primaries (colorectal carci-
noma, cholangiocarcinoma, gastrinoma, gallbladder and
pancreatic carcinoma, GIST, lung, renal, breast and laryn-
geal carcinoma) using HepaSphere 30–60 lm impregnated
with 100 mg of Doxorubicin with follow-up by post con-
trast MRI. Four patients (26.7%) had partial response, five
patients (33.3%) had stable disease and four patients
(26.7%) suffered from metastatic progression. Two patients
did not report to the follow-up MRI examination. One of
the tumors which is well responded to the treatment was
colorectal metastasis [1].
Martin RC et al., showed the results of treating unre-
sectable colorectal liver metastases refractory to systemic
therapy. This study had evaluated 55 patients with pre-
DEBIRI (drug eluting beads loaded with irinotecan) and
systemic chemotherapy (FOLFOX + Avastin - 17 patients),
(FOLFOX + Avastin and FOLFIRI + Erbitux - 14 patients)
and (FOLFOX + Avastin and FOLFIRI + Erbitux and XELOX+ Vectibex or other - 24 patients). The median treatment
dose of irinotecan was 100 mg (range 100–200 mg). The
median number of DEBIRI treatment sessions was 2 (range
1–5). Complete response was noted in 7 (12%), 7 (12%) and
8 (15%) patients 3, 6 and 12 months respectively, partial
response in 28 (53%), 21 (38%) and 14 (25%) patients 3, 6
and 12 months respectively, stable disease in 15 (30%),
19 (34%) and 23 (42%) patients 3, 6 and 12 months respec-
tively, progression of disease in 3 (5%), 8 (15%) and 10
(18%) patients 3, 6 and 12 months respectively, death of
disease in 0, 5 and 9 patients 3, 6 and 12 months respec-
tively and death of other causes in 2, 0 and 0 patients 3,
6 and 12 months respectively. The authors found that
treatment using DEBIRI is safe and effective for patients
with metastatic colorectal cancer refractory to multiple
lines of systemic therapy [17].
In this study we used the irinotecan, a topoisomerase
inhibitor, which is more specific to the colorectal hepatic
metastases; also the particles selected to be loaded with
irinotecan were drug-eluting microspheres (HepaSphere)
with good comparable results with the studies using
DEBIRI [18].
Moreover PET/CT, as a follow-up technique, is better
than triphasic CT alone or MRI as it has both qualitative
and quantitative (SUV) criteria to assess the tumor
response to therapy. PET/CT is a hybrid imaging technique,
which introduces both anatomical and functional informa-
tion. This characteristic makes PET/CT the best tool to
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after DEM TACE get larger in size yet appear totally necro-
tic with diminished activity by PET/CT that may give a false
indication of progression (pseudoprogression) in triphasic
CT or MRI alone [19].
The difference between HepaSphere and drug eluting
beads is that, the HepaSphere particles are present in a
dry form in which when hydrated (mixed with the
chemotherapeutic agent or contrast media) they get larger
size. However both can load the irinotecan and can be used
in TACE procedure for colorectal liver metastases [20].
The main limitations of this study are the small number
of patients and the relatively limited follow-up sessions
which may be attributed to the high cost of PET/CT. How-
ever, we demonstrated that DEM TACE is an effective pro-
cedure after failure of systemic chemotherapy in patients
with hepatic colorectal metastases.
5. Conclusion
Transarterial chemoembolization using drug-eluting
microspheres loaded with irinotecan is a safe and effective
salvage treatment of liver metastases from colorectal carci-
noma not responding to systemic chemotherapy.
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